Levodopa-induced dyskinesias in Parkinson disease: A population-based cohort study in Olmsted County, MN (1991-2010)
Objective: To assess the frequency of dyskinesias in a population based-cohort of Parkinson’s disease patients. Background: Levodopa-induced dyskinesias are complications that may impact quality of…Impaired stopping reversed through dopamine replacement in Parkinson’s disease
Objective: Compare the response inhibition of motor process estimated through Stop Signal Reaction Time (SSRT) in Parkinson’s disease (PD) patients and healthy participants and observe…Evaluating long-term effectiveness of carbidopa/levodopa enteral suspension in advanced Parkinson’s Disease patients: PROviDE study design and baseline characteristics
Objective: To evaluate the real-world long-term effectiveness of CLES on advanced PD patients and their caregivers. Background: Carbidopa/levodopa enteral suspension (CLES) was approved in USA…The BeyoND study: Design and baseline characteristics of a study evaluating the long-term safety of ND0612 for motor fluctuations in Parkinson’s disease
Objective: Describe the design and baseline characteristics of a long-term (1 year) study of 2 ND0612 dose regimens, with emphasis on systemic and local safety…The highly selective 5-HT2A receptor antagonist EMD-281,014 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To investigate the effect of the highly-selective serotonin 2A (5-HT2A ) receptor antagonist EMD-281,014 at alleviating L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat.…Huntington disease like 2 in South Africa
Objective: Background: Since the Huntingtin gene was identified in 1993, it has been recognized that a small proportion of patients with a clinical syndrome resembling…L-Dopa Responsiveness is Correlated to Fluorodeoxyglucose Metabolism and Dopamine Transporter Availability in Parkinson’s Disease
Objective: We aim to explore if the degree of l-dopa responsiveness would be correlated to metabolism level in specific brain areas by using 18F-FDG and…Final Safety Results of EASE LID 2 Study: Long Term Open-Label Study of ADS-5102 for Dyskinesia in Parkinson’s disease (PD) patients
Objective: The primary objective of this study was the safety and tolerability of ADS-5102 in PD patients with dyskinesia. Secondary efficacy outcome measures included MDS-UPDRS,…Weight variation in Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel infusion
Objective: To compare weight variations between three cohorts of patients with advanced Parkinson’s disease (PD): patients during their first year of treatment either with levodopa-carbidopa…Levodopa Induced Orthostatic Hypotension in Parkinson’s Disease: A Single-Dose Response Study
Objective: To determine the effect and risk factors of a single dose levodopa induced OH in PD Background: Levodopa (LD) is widely recognised as the…
- « Previous Page
- 1
- …
- 40
- 41
- 42
- 43
- 44
- …
- 57
- Next Page »